HSV: The scout and assault for digestive system tumors

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Digestive system tumors (DSTs) represent over 25% of malignant tumors, causing significant global morbidity and mortality.
• Conventional treatments like chemotherapy, radiotherapy, and surgery offer limited efficacy and poor prognoses for DSTs.
• Oncolytic virus therapy is an emerging immunotherapy demonstrating remarkable anti-tumor activity.

Purpose of the Study:

• To review the therapeutic potential of herpes simplex virus (HSV) in treating various digestive system tumors (DSTs).
• To discuss the specific application of HSV-1, based on recent research, for DST treatment.
• To explore the role of HSV in cancer detection and future therapeutic possibilities.

Main Methods:

• Literature review of recent studies on herpes simplex virus (HSV) and its application in oncolytic virus therapy.
• Analysis of research focusing on HSV-1 efficacy against different types of digestive system tumors (DSTs).
• Discussion of HSV's potential role in cancer diagnostics and future research directions.

Main Results:

• Herpes simplex virus (HSV), particularly HSV-1, exhibits significant anti-tumor effects against multiple digestive system tumors (DSTs).
• HSV demonstrates potential beyond therapy, including a role in cancer detection.
• Recent studies highlight HSV's promise in overcoming limitations of traditional DST treatments.

Conclusions:

• Herpes simplex virus (HSV) presents a promising oncolytic virus therapy for digestive system tumors (DSTs), offering an alternative to conventional treatments.
• Further research into HSV-1 applications could lead to improved therapeutic strategies and diagnostic tools for DSTs.
• HSV holds potential for advancing cancer treatment and detection in the field of oncology.